Spectral AI’s DeepView System Gains Traction at Burn Association Conference

Event summary

  • Spectral AI showcased its DeepView® System at the 2026 American Burn Association Annual Meeting, attended by 2,200 clinicians and researchers.
  • The DeepView System, an AI-driven diagnostic tool for burn wounds, was featured in multiple podium and poster presentations.
  • Dr. Christopher J. Lewis highlighted the system’s real-world usability and non-contact imaging capabilities.
  • Spectral AI submitted its De Novo 510(k) marketing clearance application for the DeepView System to the FDA in June 2025.

The big picture

Spectral AI’s DeepView System represents a shift toward AI-driven diagnostics in burn care, potentially reducing healthcare costs and improving patient outcomes. The company’s focus on regulatory clearance and clinical validation aligns with broader trends in medical technology toward faster, more accurate treatment decisions. The system’s non-contact imaging and real-world usability could set a new standard for burn wound assessment.

What we're watching

Regulatory Approval
The pace at which the FDA reviews Spectral AI’s De Novo 510(k) application will determine the system’s commercial availability.
Clinical Adoption
Whether the DeepView System can sustain momentum in clinical settings following positive conference feedback.
Competitive Positioning
How Spectral AI differentiates its AI-driven diagnostics in a crowded medical device market.

Related topics

Medical Devices